New industrial grade of liquid Chloroperoxidase

Bio-Research Products announced today that it will add to its Chloroperoxidase (CPO) offerings a lower cost, industrial grade for application to organic syntheses such as oxidations and halogenations. Dr. Bryce Cunningham, President, said that "there has been an increased interest in CPO from industrial and pharmaceutical markets which has prompted us to establish a grade that better meets their needs."

Dr. Harold Durkin, Business Development Manager, describes Chloroperoxidase as a catalyst for oxidation of alcohols and double bonds that allows these reactions to proceed at room temperature to high yields without by-products. "This catalyst fits in well with the green chemistry movement and should be of particular interest to the fragrance industry where oxidation of primary alcohols to aldehydes is a key route to aroma chemicals."

The new industrial grade of liquid Chloroperoxidase is designated as Catalog #502 and has an Rz value of ~1.2 and a price of $7.50 per KU in gram quantities. Bio-Research Products already markets a liquid CPO (#501) and a lyo CPO (#503). Bio-Research Products' CPO enzyme is derived from Caldariomyces fumago.

Source:

Bio-Research Products

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy